Experimental HCV Drugs
Experimental HCV Drugs
Janssen Acquires GSK NS5A Inhibitor Candidate for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 11 October 2013 00:00
- Written by Janssen
Janssen Pharmaceuticalsannounced this week that it has purchased a Phase 2 hepatitis C virus (HCV) NS5A inhibitor candidate, GSK2336805,from GlaxoSmithKline. Janssen is also developing the promising HCV protease inhibitor simeprevir (formerly TMC435), which is currently awaiting approval in the U.S. and Europe.
IDWeek 2013: Daclatasvir Is Effective Against HCV with Interferon or in All-oral Regimen
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 08 October 2013 00:00
- Written by Liz Highleyman
A short 12- or 16-week triple regimen of daclatasvir plus pegylated interferon/ribavirin cured more people than a 24-week course of pegylated interferon/ribavirin alone, while an interferon-free regimen containing daclatasvir, asunaprevir, and BMS-791325 produced sustained response rates of around 90%, researchers reported at the Second IDWeek conference last week in San Francisco.
Simeprevir for Hepatitis C Approved in Japan, Cobicistat Gets Nod in Europe
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 27 September 2013 00:00
- Written by Medivir, Gilead Sciences
The HCV protease inhibitor simeprevir (formerly TMC435) has been granted approval in Japan for the treatment of people with genotype 1 chronic hepatitis C, Medivir announced this week. In related news, Gilead Sciences said their new pharmacoenhancer cobicistat -- brand name Tybost -- has been approved as a stand-alone drug in the European Union for use as a booster for certain HIV protease inhibitors.
Adding Danoprevir Boosts Response to Interferon-based Therapy for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 01 October 2013 00:00
- Written by Liz Highleyman
Combining the second-generation hepatitis C virus (HCV) protease inhibitor danoprevir with pegylated interferon and ribavirin raised the sustained virological response rate to 85% for genotype 1 patients, without much increase in toxicity, according to a report in the October 2013 issue of Gastroenterology.
Phase 2 Study Looks at Faldaprevir + Deleobuvir + PPI-668 for Genotype 1a Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 17 September 2013 00:00
- Written by Boehringer Ingelheim
All participants are now enrolled in a Phase 2a clinical trial testing an interferon-free oral regimen containing Boehringer Ingelheim's faldaprevir (BI 201335) and deleobuvir (BI 207127) plus Presidio's NS5A inhibitor PPI-668, with or without ribavirin, according to a company announcement.
More Articles...
- Simeprevir + Sofosbuvir Works Well for Patients with Advanced Fibrosis
- Sofosbuvir + Ribavirin Dual Regimen Cures HCV in Difficult-to-Treat Hepatitis C Patients
- Faldaprevir + Deleobuvir All-oral Regimen Works Well Against Genotype 1b HCV
- FDA Puts Partial Hold on HCV Drug VX-135 Due to Liver Toxicity at Higher Doses
Web Design and Development by